Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab

被引：0
|
作者：
Gudesblatt, Mark [1 ,2 ]
Zarif, Myassar [2 ]
Bumstead, Barbara [2 ]
Buhse, Marijean [2 ]
Kaczmarek, Olivia [2 ]
Li, Hanyue [3 ]
Sun, Zhaonan [3 ]
Scott, Nicole [3 ]
Mendoza, Jason P. [3 ]
Avila, Robin L. [3 ]
机构：
[1] Langone South Shore Neurol Associates, 77 Medford Ave, Patchogue, NY 11772 USA
[2] NYU Langone South Shore Neurol Associates PC, Patchogue, NY USA
[3] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL | 2023年 / 9卷 / 04期
关键词：
Multiple sclerosis; natalizumab; COVID-19; vaccine;
D O I：
10.1177/20552173231218117
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Severe Thrombocytopenia Two Weeks Following Immunization with the Janssen Ad26.CoV2.S Vaccine
    Antonios, Bana
    Zimmer, Markie
    Herrman, Emma
    Berghea, Ramona
    CASE REPORTS IN HEMATOLOGY, 2022, 2022
  • [42] Correspondence Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
    Maglione, Alessandro
    Morra, Marta
    Meroni, Raffaella
    Matta, Manuela
    Clerico, Marinella
    Rolla, Simona
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 61
  • [43] Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis
    Ciampi, Ethel
    Uribe-San-Martin, Reinaldo
    Soler, Bernardita
    Garcia, Lorena
    Guzman, Jorge
    Pelayo, Carolina
    Jurgensen, Lukas
    Guzman, Ignacio
    Vera, Francisco
    Galleguillos, Lorna
    Carcamo, Claudia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
  • [44] Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study
    Jorge Millán-Pascual
    Gabriel Valero-López
    Francisca Iniesta-Martinez
    Maria Fuensanta Hellin-Gil
    Judith Jimenez-Veiga
    Isabel Alejandra López-Tovar
    Ana Morales-Ortiz
    José. E. Meca-Lallana
    Neurology and Therapy, 2024, 13 : 153 - 164
  • [45] SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
    Achtnichts, Lutz
    Ovchinnikov, Arkady
    Jakopp, Barbara
    Oberle, Michael
    Nedeltchev, Krassen
    Fux, Christoph Andreas
    Sellner, Johann
    Findling, Oliver
    VACCINES, 2022, 10 (02)
  • [46] Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study
    Millan-Pascual, Jorge
    Valero-Lopez, Gabriel
    Iniesta-Martinez, Francisca
    Hellin-Gil, Maria Fuensanta
    Jimenez-Veiga, Judith
    Lopez-Tovar, Isabel Alejandra
    Morales-Ortiz, Ana
    Meca-Lallana, Jose. E.
    NEUROLOGY AND THERAPY, 2024, 13 (01) : 153 - 164
  • [47] Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
    Bajwa, Hamza Mahmood
    Novak, Frederik
    Nilsson, Anna Christine
    Nielsen, Christian
    Holm, Dorte K.
    Ostergaard, Kamilla
    Witt, Agnes Hauschultz
    Byg, Keld-Erik
    Johansen, Isik S.
    Mittl, Kristen
    Rowles, William
    Zamvil, Scott S.
    Bove, Riley
    Sabatino, Joseph J.
    Sejbaek, Tobias
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [48] Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
    Hyun, Hakjun
    Choi, Min Joo
    Heo, Jung Yeon
    Seo, Yu Bin
    Nham, Eliel
    Yoon, Jin Gu
    Seong, Hye
    Noh, Ji Yun
    Cheong, Hee Jin
    Kim, Woo Joo
    Choi, Ju-Yeon
    Lee, Young Jae
    Lee, Hye Won
    Kim, Sung Soon
    Kim, Byoungguk
    Song, Joon Young
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (27)
  • [49] Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients
    Blaszczuk, Agata
    Sikora, Dominika
    Kis, Jacek
    Stepien, Ewa
    Drop, Bartlomiej
    Polz-Dacewicz, Malgorzata
    VACCINES, 2023, 11 (04)
  • [50] Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response
    Reimann, Patrick
    Ulmer, Hanno
    Mutschlechner, Beatrix
    Benda, Magdalena
    Severgnini, Luciano
    Volgger, Andreas
    Lang, Theresia
    Atzl, Michele
    Huynh, Minh
    Gasser, Klaus
    Grabher, Claudia
    Mink, Sylvia
    Fraunberger, Peter
    Petrausch, Ulf
    Hartmann, Bernd
    Winder, Thomas
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (03) : 577 - 584
12345